A phase 1/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed/refractory AML after allogeneic HCT

Publication Date

2026

Content Type

article

PubMed ID:

41636724

Additional Authors:

Additional Authors and Institutional Affiliations

This document is currently not available here.

Share

COinS